In June 2023, the Food and Drug Administration (“FDA”) released Draft Guidance outlining its current view of the psychedelic research landscape. The Draft Guidance is aimed at researchers conducting clinical trials using psychedelic drugs. While the FDA does not define psychedelics, it indicated that the shorthand term “psychedelic” includes “classic psychedelics,” which are typically understood to... READ MORE
FDA Outlines Considerations for Conducting Clinical Investigations Using Psychedelic Drugs
Posted on September 15, 2023 in Health Law News
Published by: Hall Render
